Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published...

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Immune checkpoint inhibitors (ICIs) are a major advancement for advanced/metastatic non-small-cell lung cancer (NSCLC) lacking driver alterations.
• However, only a subset of patients benefits durably, necessitating improved patient selection for immunotherapy.
• Unresolved issues remain in personalizing ICI treatment for individual patients.

Purpose of the Study:

• To review baseline clinical and demographic factors influencing ICI efficacy in NSCLC patients.
• To identify patient characteristics that may predict response or resistance to immunotherapy.
• To enhance understanding of tumor-specific immune responses for better patient stratification.

Main Methods:

• Analysis of data from pivotal randomized clinical trials (RCTs) involving ICIs.
• Discussion of patient baseline features: sex, age, ECOG performance status, smoking history, and metastasis sites (liver, bone, brain).
• Evaluation of how these factors impact efficacy outcomes in NSCLC patients treated with ICIs.

Main Results:

• Specific baseline factors such as sex, age, performance status, smoking history, and metastatic site (liver, bone, brain) can influence ICI efficacy.
• These factors, often overlooked due to the overall success of ICIs, are critical for understanding treatment outcomes.
• Identifying these clinical drivers is essential for improving patient stratification in immunotherapy.

Conclusions:

• Personalizing immunotherapy selection in NSCLC requires careful consideration of patient baseline characteristics.
• Factors like age, sex, smoking, and metastasis location significantly impact ICI treatment effectiveness.
• Further evaluation of these clinical drivers is crucial for optimizing patient stratification and improving immunotherapy outcomes in NSCLC.